Acute Crit Care.  2023 Aug;38(3):251-260. 10.4266/acc.2023.00955.

Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it

• Joo SJ

• KMID: 2547018
• DOI: http://doi.org/10.4266/acc.2023.00955

Abstract

Most of the evidences for beneficial effects of beta-blockers in patients with acute myocardial infarction (AMI) were from the clinical studies published in the pre-reperfusion era when anti-platelet drugs, statins or inhibitors of renin-angiotensin-aldosterone system which are known to reduce cardiovascular mortality of patients with AMI were not introduced. In the reperfusion era, beta-blockers’ benefit has not been clearly shown except in patients with reduced ejection fraction (EF; ≤40%). In the era of the early reperfusion therapy for AMI, a number of patients with mildly reduced EF (>40%, <50%) or preserved EF (≥50%) become increasing. However, because no randomized clinical trials are available until now, the benefit and the optimal duration of oral treatment with beta-blockers in patients with mildly reduced or preserved EF are questionable. Registry data have not showed the association of oral beta-blocker therapy with decreased mortality in survivors without heart failure or left ventricular systolic dysfunction after AMI. In the Korea Acute Myocardial Infarction Registry-National Institute of Health of in-hospital survivors after AMI, the benefit of beta-blocker therapy at discharge was shown in patients with reduced or mildly reduced EF, but not in those with preserved EF, which provides new information about beta-blocker therapy in patients without reduced EF. However, clinical practice can be changed when the results of appropriate randomized clinical trials are available. Ongoing clinical trials may help to answer the unresolved issues of beta-blocker therapy in patients with AMI.

Keyword

beta-blocker; myocardial infarction; outcome; ventricular ejection fraction

Figure

• 

  Figure 1. Mechanisms of beta-blocker therapy to improve myocardial ischemia in acute myocardial infarction. ↓: decrease;↑: increase.

• 

  Figure 2. Unadjusted Kaplan-Meier curves and adjusted hazard ratios (HR) for 1-year major adverse cardiac events in the entire cohort with vs. without beta-blockers (BB) according to left ventricular ejection fraction (LVEF). (A) LVFE ≤40% (n=1,670 patients). (B) 40%< LVEF <50% (n=2,904 patients). (C) LVEF ≥50% (n=7,626 patients). CI: confidence interval. Adapted from Joo et al. Eur Heart J Cardiovasc Pharmacother 2021;7:475-82 [22].

Reference

1. Jneid H, Addison D, Bhatt DL, Fonarow GC, Gokak S, Grady KL, et al. 2017 AHA/ACC clinical performance and quality measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2017; 70:2048–90.

2. Kim SM, Jang WM, Ahn HA, Park HJ, Ahn HS. Korean National Health Insurance value incentive program: achievements and future directions. J Prev Med Public Health. 2012; 45:148–55.

3. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318:1730–7.

4. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012; 308:1340–9.

5. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014; 127:939–53.

6. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357:1385–90.

7. Antman EM, Loscalzo J. ST-segment elevation myocardial infarction. In: Loscalzo J, Fauci A, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 21st ed. McGraw Hill; 2022. p. 2053-66.

8. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol: a multicentre international study. Br Med J. 1975; 3:735–40.

9. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981; 304:801–7.

10. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet. 1981; 2:823–7.

11. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982; 247:1707–14.

12. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986; 2:57–66.

13. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012; 60:e44–164.

14. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366:1622–32.

15. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:529–55.

16. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39:119–77.

17. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:2354–94.

18. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42:1289–367.

19. McMurray J, Køber L, Robertson M, Dargie H, Colucci W, Lopez-Sendon J, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005; 45:525–30.

20. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42:3599–726.

21. Cleland JG, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJ, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018; 39:26–35.

22. Joo SJ, Kim SY, Choi JH, Park HK, Beom JW, Lee JG, et al. Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021; 7:475–82.

23. Yang JH, Hahn JY, Song YB, Choi SH, Choi JH, Lee SH, et al. Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv. 2014; 7:592–601.

24. Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, et al. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016; 354:i4801.

25. Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, et al. β-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017; 69:2710–20.

26. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376:875–85.

27. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014; 371:1091–9.

28. Nambiar L, Meyer M. β-Blockers in myocardial infarction and coronary artery disease with a preserved ejection fraction: recommendations, mechanisms, and concerns. Coron Artery Dis. 2018; 29:262–70.

29. Montenegro Sá F, Carvalho R, Ruivo C, Santos LG, Antunes A, Soares F, et al. Beta-blockers for post-acute coronary syndrome mid-range ejection fraction: a nationwide retrospective study. Eur Heart J Acute Cardiovasc Care. 2019; 8:599–605.

30. Joo SJ, Kim SY, Lee JG, Beom JW, Choi JH, Park HK, et al. Association of the medical therapy with beta-blockers or inhibitors of renin-angiotensin system with clinical outcomes in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction. Medicine (Baltimore). 2022; 101:e30846.

31. Writing Committee Members, Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023; 82:833–955.

32. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41:407–77.

33. Kim J, Kang D, Park H, Kang M, Park TK, Lee JM, et al. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J. 2020; 41:3521–9.

34. Holt A, Blanche P, Zareini B, Rajan D, El-Sheikh M, Schjerning AM, et al. Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. Eur Heart J. 2021; 42:907–14.

35. Joo SJ, Boo KY, Beom JW, Lee JG, Choi JH, Kim SY, et al. Optimal medical therapy for patients with acute myocardial infarction beyond one year after the initial attack. J Am Coll Cardiol. 2022; 79(9_Supplement):952.

36. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol. 2015; 66:1431–41.

37. Goldberger JJ, Subačius H, Marroquin OC, Beau SL, Simonson J; OBTAIN (Outcomes of Beta‐Blocker Therapy After Myocardial Infarction) Investigators. One-year landmark analysis of the effect of beta-blocker dose on survival after acute myocardial infarction. J Am Heart Assoc. 2021; 10:e019017.

38. Mars K, Wallert J, Held C, Humphries S, Pingel R, Jernberg T, et al. Association between β-blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry. Eur Heart J Acute Cardiovasc Care. 2021; 10:372–9.